Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of pembrolizumab and chemotherapy with or without MK-4830 as neoadjuvant/adjuvant treatment for high-grade serous ovarian cancer
MOH_2022-05-30_011828Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mk-4830, pembrolizumab, carboplatin and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Merck & Co. Primary endpoint: Safety of MK-4830 in combination with pembrolizumab and chemotherapy. Started Mar 2022; status: active, not recruiting.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2022-05-30_011828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-30_011828.